Disclosed are devices, arrangements and methods for quantifying the concentration of an analyte present in bodily fluid, including: an assay pad having at least one chemical reagent capable of producing a detectable signal in the form of a reaction spot upon reaction with the analyte; a light source; a detector array; a processor; and a memory in communication with the processor, the memory comprising: (a) at least one value indicative of one or more of: (i) the level of hematocrit contained in the sample; (ii) the volume of the sample applied to the assay pad; or (iii) imperfections present in the reaction spot; and (b) at least one algorithm for calculating the concentration of the analyte contained in the sample.

A reagent, test paper, a reagent kit, and a test paper kit for detecting a sulfhydryl compound, and a preparation method thereof are provided. The reagent is obtained by mixing a phosphotungstic acid (PTA) reagent, an acetate buffer, and a shield reagent in a specified ratio. The test paper is composed of porous water-absorbent paper and a dry detection reagent dispersed thereon. The reagent is based on principle innovation. When in use, the reagent is directly mixed with urine to be tested in a volume ratio of 2:1, a resulting mixture is allowed to stand for 10 min to 15 min, and then a result can be directly determined by naked eyes. The reagent overcomes the shortcoming of requiring a control sample to assist in the determination of a result in existing methods, and has the advantages of simple operation, safety and non-toxicity, and rapid detection.

A system for monitoring an analyte concentration in liquid is provided. The system includes a coupon comprising an absorbent body with a window through the absorbent body wherein the liquid is maintained in said window by capillary action and surface tension. A reactant is in the absorbent body wherein the reactant is capable of diffusing into the window to react with an analyte in the liquid, or the reactant is able to react with the analyte within the coupon itself, with color-indicating by-products of the reaction diffusing into the window, wherein the analyte is present in an analyte concentration, to form a reactant with a color wherein the color has an intensity which correlates to the analyte concentration. A light source is provided which is capable of passing light into the window wherein the light is attenuated by the color proportional to the analyte concentration to form attenuated light. A detector is provided which is capable measuring an intensity of the attenuated light. Alternatively, the color change can be read by eye and compared to a color chart relating the color to an analyte concentration.

The invention provides a test kit and a test method using the same. The test kit utilized for detecting the neutralizing antibody against COVID-19 has high sensitivity and specificity. The test kit especially comprises antigen-complex that essentially consists of a receptor binding domain (RBD) located in COVID-19 spike glycoprotein, two N-terminal domains located in COVID-19 spike glycoprotein and a domain between the RBD and the N-terminal domain (NTD). The test kit may quantitatively determine the titer of the neutralizing antibody against COVID-19.

The technology in part relates to diagnostic test devices and in part relates to test devices that include a lateral flow test strip. The technology in part relates to a test device system that incorporates sample collection, delivery, measuring, processing, incubation, flow regulation and analyzing a sample of interest in a single assembly.

A method for localizing a test region of interest on an assay membrane to determine the contours of the test region and enable calibration of the location of the test region such that the same region can be localized to image an analyte of interest after an assay run. Pre-localization of the test region limits the contours of the detection area to only the test region with a reasonable margin such that background noise received by the detector can be minimized. By limiting the region of detection to a pre-localized test region improved accuracy can be achieved in flow assay membrane tests, in particular in automated analyzer systems.

The present disclosure is drawn to an isolated complementary DNA (cDNA) of a nucleic acid molecule that can comprise a nucleotide sequence that is at least 85% identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or a combination thereof. In one embodiment, a primer set for reverse transcription loop-mediated isothermal amplification (RT-LAMP) analysis can comprise a forward inner primer (FIP) sequence, a backward inner primer (BIP) sequence, a forward outer primer (F3) sequence, a backward outer primer (B3) sequence, a forward loop primer (LF) sequence, and a backward loop primer (LB) sequence. In another embodiment, a method of detecting a target pathogen can comprise providing a primer set.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

A device (1) for sensing an analyte, the device (1) comprises at least a sample inlet (10) for receiving a sample, affinity probes (111) selected to have a preferential binding to the analyte, a transducer (11) sensitive to a characteristic of the analyte and/or a label attached to the analyte, the transducer not being a FET transducer, and a desalting unit (13) for desalting the received sample.

The present invention provides a method of producing a test strip for measuring a calcium concentration in a body fluid test sample obtained from a living body (human or animal) by a colormetric change, and a test strip for measuring a calcium concentration in a human or animal body fluid test strip by a colormetric change.